Get the Stockscreener App
3.39
0.00%
0.00
After Hours:
3.08
-0.31
-9.14%
Genelux Corp stock is traded at $3.39, with a volume of 305.91K.
It is up +0.00% in the last 24 hours and down -26.94% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
See More
Previous Close:
$3.39
Open:
$3.38
24h Volume:
305.91K
Relative Volume:
1.34
Market Cap:
$129.00M
Revenue:
-
Net Income/Loss:
$-27.66M
P/E Ratio:
-3.5684
EPS:
-0.95
Net Cash Flow:
$-24.36M
1W Performance:
-22.25%
1M Performance:
-26.94%
6M Performance:
+16.90%
1Y Performance:
+26.49%
1-Day Range:
$3.345
$3.71
1-Week Range:
$3.32
$4.9883
52-Week Range:
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.39 | 129.00M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Lake Street | Buy |
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
View All
Genelux Corp Stock (GNLX) Latest News
Genelux stock falls after announcing proposed public offering - Investing.com
Genelux announces proposed public offering of common stock - Investing.com
Genelux Corporation Announces Proposed Public Offering of Common Stock - MarketScreener
Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan
Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - Nasdaq
Genelux data update indicates disease early control, says H.C. Wainwright - TipRanks
Genelux reports encouraging interim data for Olvi-Vec trials - MSN
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer - TipRanks
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data - Investing.com India
Genelux reports interim data of systemic administration of Olvi-Vec - TipRanks
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials - TipRanks
Experimental treatment shrank lung tumors up to 85% in early trial - Stock Titan
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - Sahm
Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Genelux appoints Jason Litten as chief medical officer By Investing.com - Investing.com Nigeria
Genelux Appoints Veteran Oncologist Jason Litten as CMO - TipRanks
Genelux appoints Jason Litten as CMO - TipRanks
Genelux Corporation Announces Change of Chief Medical Officer - MarketScreener
Genelux appoints Jason Litten as chief medical officer - Investing.com India
Genelux Corporation Appoints Dr. Jason Litten as Chief Medical Officer to Advance Olvi-Vec Development - Quiver Quantitative
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - GlobeNewswire Inc.
GENELUX CORP : BENCHMARK CUTS TARGET PRICE TO $23 FROM $25 - 富途牛牛
How interest rate cuts could boost Genelux Corporation stockAnalyst Upgrades & AI Alerts You Can Actually Trust - Bollywood Helpline
Flputnam Investment Management Co. Raises Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux (NASDAQ:GNLX) Cut to Sell at Wall Street Zen - Defense World
Cappello, Genelux CTO, sells $14k in GNLX stock By Investing.com - Investing.com Nigeria
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 4,509 Shares - MarketBeat
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 12,673 Shares of Stock - MarketBeat
Genelux president sells $66k in GNLX stock By Investing.com - Investing.com India
Genelux SVP, Yu Yong, sells shares worth $16k By Investing.com - Investing.com Australia
Genelux SVP, Yu Yong, sells shares worth $16k - Investing.com
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
VP Yu Surrenders 4,192 Of Genelux Corp [GNLX] - TradingView — Track All Markets
Genelux reports Q3 EPS (21c), consensus (21c) - MSN
Lake Street Sticks to Their Buy Rating for Genelux Corp. (GNLX) - The Globe and Mail
Genelux price target raised to $20 from $10 at Maxim - MSN
Genelux (NASDAQ:GNLX) Director Sells $50,000.00 in Stock - MarketBeat
Genelux (GNLX) Stock Analysis Report | Financials & Insights - Benzinga
GENELUX Corp Director Thomas John Sells 10,000 Shares - TradingView
Dir Thomas Sells 10,000 ($50K) Of Genelux Corp [GNLX] - TradingView
Wall Street analysts’ outlook for Genelux Corp (GNLX) - Setenews
Global Retirement Partners LLC Acquires Shares of 228,676 Genelux Corporation $GNLX - MarketBeat
MAI Capital Management Boosts Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux Corporation Executives to Participate in Fireside Chat at Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative
Genelux (NASDAQ: GNLX) sets Dec. 3 fireside chat at Piper Sandler 37th Conference - Stock Titan
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment - MSN
What risks investors should watch in Genelux Corporation stockForecast Cut & Daily Technical Forecast Reports - newser.com
Genelux Corporation's (NASDAQ:GNLX) 16% loss last week hit both individual investors who own 58% as well as institutions - simplywall.st
Genelux initiated with a Buy at Titan Partners - MSN
Combining machine learning predictions for Genelux Corporation2025 Breakouts & Breakdowns & Weekly Breakout Opportunity Watchlist - newser.com
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):